25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Evoke Pharma Inc
Buy, Hold or Sell?

Let's analyze Evoke Pharma Inc together

I guess you are interested in Evoke Pharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Evoke Pharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Evoke Pharma Inc

I send you an email if I find something interesting about Evoke Pharma Inc.

1. Quick Overview

1.1. Quick analysis of Evoke Pharma Inc (30 sec.)










1.2. What can you expect buying and holding a share of Evoke Pharma Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$3.13
Expected worth in 1 year
$6.53
How sure are you?
27.5%

+ What do you gain per year?

Total Gains per Share
$3.40
Return On Investment
78.8%

For what price can you sell your share?

Current Price per Share
$4.31
Expected price per share
$3.54 - $11.40
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Evoke Pharma Inc (5 min.)




Live pricePrice per Share (EOD)
$4.31
Intrinsic Value Per Share
$15.57 - $64.16
Total Value Per Share
$18.71 - $67.29

2.2. Growth of Evoke Pharma Inc (5 min.)




Is Evoke Pharma Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$4.3m$1.4m$523.5k26.3%

How much money is Evoke Pharma Inc making?

Current yearPrevious yearGrowGrow %
Making money-$1.5m-$1.9m$409.9k26.7%
Net Profit Margin-77.2%-199.7%--

How much money comes from the company's main activities?

2.3. Financial Health of Evoke Pharma Inc (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Evoke Pharma Inc?

Welcome investor! Evoke Pharma Inc's management wants to use your money to grow the business. In return you get a share of Evoke Pharma Inc.

First you should know what it really means to hold a share of Evoke Pharma Inc. And how you can make/lose money.

Speculation

The Price per Share of Evoke Pharma Inc is $4.31. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Evoke Pharma Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Evoke Pharma Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.13. Based on the TTM, the Book Value Change Per Share is $0.85 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.48 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Evoke Pharma Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.94-21.8%-1.10-25.5%-0.54-12.5%-0.94-21.9%-1.72-39.8%
Usd Book Value Change Per Share1.1827.4%0.8519.7%-0.48-11.1%0.030.7%-0.28-6.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share1.1827.4%0.8519.7%-0.48-11.1%0.030.7%-0.28-6.5%
Usd Price Per Share4.76-1.74-1.90-1.94-2.59-
Price to Earnings Ratio-1.27--0.48--0.88--0.60--0.52-
Price-to-Total Gains Ratio4.04-0.47--4.04--2.16--1.08-
Price to Book Ratio1.52-0.14-2.54--0.44-0.15-
Price-to-Total Gains Ratio4.04-0.47--4.04--2.16--1.08-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.31
Number of shares232
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.850.03
Usd Total Gains Per Share0.850.03
Gains per Quarter (232 shares)196.936.51
Gains per Year (232 shares)787.7126.03
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1078877802616
201575156605242
302363235407868
4031513142010494
50393939300130120
60472647180156146
70551455060182172
80630262940208198
90708970820234224
100787778700260250

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.048.00.00.0%
Book Value Change Per Share2.02.00.050.0%3.09.00.025.0%4.016.00.020.0%11.029.00.027.5%14.034.00.029.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.048.00.0%
Total Gains per Share2.02.00.050.0%3.09.00.025.0%4.016.00.020.0%11.029.00.027.5%14.034.00.029.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Evoke Pharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.1790.849+39%-0.479+141%0.028+4105%-0.278+124%
Book Value Per Share--3.1342.146+46%0.439+613%1.225+156%2.630+19%
Current Ratio--1.4371.590-10%5.201-72%4.123-65%4.726-70%
Debt To Asset Ratio--0.6900.889-22%0.874-21%0.789-13%0.650+6%
Debt To Equity Ratio--2.2262.085+7%5.326-58%2.181+2%1.786+25%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--8236035.3202128052.258+287%5905113.925+39%5992056.928+37%6632552.013+24%
Eps---0.938-1.097+17%-0.541-42%-0.945+1%-1.716+83%
Ev To Ebitda Ratio---1.602-0.419-74%-0.828-48%-0.774-52%-0.663-59%
Ev To Sales Ratio--0.7760.197+293%1.679-54%infnan%infnan%
Free Cash Flow Per Share---0.585-1.166+99%-0.477-18%-0.815+39%-1.428+144%
Free Cash Flow To Equity Per Share--1.5441.713-10%-0.486+131%0.469+229%0.241+541%
Gross Profit Margin--1.0001.203-17%1.0000%1.092-8%1.388-28%
Intrinsic Value_10Y_max--64.158--------
Intrinsic Value_10Y_min--15.572--------
Intrinsic Value_1Y_max---1.545--------
Intrinsic Value_1Y_min---4.505--------
Intrinsic Value_3Y_max--1.435--------
Intrinsic Value_3Y_min---8.362--------
Intrinsic Value_5Y_max--11.742--------
Intrinsic Value_5Y_min---6.520--------
Market Cap3531062.320-89%6663438.3202848932.008+134%6360190.675+5%4828078.828+38%4081965.788+63%
Net Profit Margin---0.494-0.772+56%-1.997+304%-8.363+1591%-4.181+746%
Operating Margin----1.3350%-2.4880%-8.3560%-4.1780%
Operating Ratio--1.4841.739-15%2.852-48%8.910-83%4.455-67%
Pb Ratio1.375-10%1.5190.143+964%2.537-40%-0.445+129%0.151+908%
Pe Ratio-1.149+9%-1.269-0.483-62%-0.878-31%-0.599-53%-0.518-59%
Price Per Share4.310-10%4.7601.737+174%1.903+150%1.940+145%2.592+84%
Price To Free Cash Flow Ratio-1.842+9%-2.035-0.774-62%-1.029-49%-0.824-59%-0.621-69%
Price To Total Gains Ratio3.654-10%4.0360.467+763%-4.043+200%-2.162+154%-1.079+127%
Quick Ratio--1.3681.394-2%4.676-71%3.822-64%4.446-69%
Return On Assets---0.093-0.151+63%-0.204+120%-0.228+146%-0.264+185%
Return On Equity---0.299-0.307+2%-1.264+323%-0.531+77%-0.632+111%
Total Gains Per Share--1.1790.849+39%-0.479+141%0.028+4105%-0.278+124%
Usd Book Value--4387136.0001992431.500+120%1468849.750+199%2619943.150+67%3538315.275+24%
Usd Book Value Change Per Share--1.1790.849+39%-0.479+141%0.028+4105%-0.278+124%
Usd Book Value Per Share--3.1342.146+46%0.439+613%1.225+156%2.630+19%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.938-1.097+17%-0.541-42%-0.945+1%-1.716+83%
Usd Free Cash Flow---818690.000-1331201.000+63%-1596299.500+95%-1796515.250+119%-1949115.650+138%
Usd Free Cash Flow Per Share---0.585-1.166+99%-0.477-18%-0.815+39%-1.428+144%
Usd Free Cash Flow To Equity Per Share--1.5441.713-10%-0.486+131%0.469+229%0.241+541%
Usd Market Cap3531062.320-89%6663438.3202848932.008+134%6360190.675+5%4828078.828+38%4081965.788+63%
Usd Price Per Share4.310-10%4.7601.737+174%1.903+150%1.940+145%2.592+84%
Usd Profit---1312390.000-1536707.250+17%-1946693.000+48%-2171797.100+65%-2368218.925+80%
Usd Revenue--2654186.0002154259.000+23%1075251.500+147%813570.650+226%406785.325+552%
Usd Total Gains Per Share--1.1790.849+39%-0.479+141%0.028+4105%-0.278+124%
 EOD+2 -6MRQTTM+27 -9YOY+26 -95Y+28 -710Y+27 -8

3.3 Fundamental Score

Let's check the fundamental score of Evoke Pharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.149
Price to Book Ratio (EOD)Between0-11.375
Net Profit Margin (MRQ)Greater than0-0.494
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.368
Current Ratio (MRQ)Greater than11.437
Debt to Asset Ratio (MRQ)Less than10.690
Debt to Equity Ratio (MRQ)Less than12.226
Return on Equity (MRQ)Greater than0.15-0.299
Return on Assets (MRQ)Greater than0.05-0.093
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Evoke Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.872
Ma 20Greater thanMa 504.680
Ma 50Greater thanMa 1005.111
Ma 100Greater thanMa 2005.078
OpenGreater thanClose4.160
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Evoke Pharma Inc

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Fundamental data was last updated by Penke on 2024-11-14 16:17:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Evoke Pharma Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Evoke Pharma Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -49.4% means that $-0.49 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Evoke Pharma Inc:

  • The MRQ is -49.4%. The company is making a huge loss. -2
  • The TTM is -77.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-49.4%TTM-77.2%+27.7%
TTM-77.2%YOY-199.7%+122.5%
TTM-77.2%5Y-836.3%+759.1%
5Y-836.3%10Y-418.1%-418.1%
4.3.1.2. Return on Assets

Shows how efficient Evoke Pharma Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Evoke Pharma Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • -9.3% Return on Assets means that Evoke Pharma Inc generated $-0.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Evoke Pharma Inc:

  • The MRQ is -9.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -15.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.3%TTM-15.1%+5.9%
TTM-15.1%YOY-20.4%+5.3%
TTM-15.1%5Y-22.8%+7.7%
5Y-22.8%10Y-26.4%+3.6%
4.3.1.3. Return on Equity

Shows how efficient Evoke Pharma Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Evoke Pharma Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • -29.9% Return on Equity means Evoke Pharma Inc generated $-0.30 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Evoke Pharma Inc:

  • The MRQ is -29.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -30.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-29.9%TTM-30.7%+0.7%
TTM-30.7%YOY-126.4%+95.8%
TTM-30.7%5Y-53.1%+22.4%
5Y-53.1%10Y-63.2%+10.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Evoke Pharma Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Evoke Pharma Inc is operating .

  • Measures how much profit Evoke Pharma Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Evoke Pharma Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Evoke Pharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-133.5%+133.5%
TTM-133.5%YOY-248.8%+115.3%
TTM-133.5%5Y-835.6%+702.1%
5Y-835.6%10Y-417.8%-417.8%
4.3.2.2. Operating Ratio

Measures how efficient Evoke Pharma Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.48 means that the operating costs are $1.48 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Evoke Pharma Inc:

  • The MRQ is 1.484. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.739. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.484TTM1.739-0.254
TTM1.739YOY2.852-1.114
TTM1.7395Y8.910-7.171
5Y8.91010Y4.455+4.455
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Evoke Pharma Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Evoke Pharma Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.44 means the company has $1.44 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Evoke Pharma Inc:

  • The MRQ is 1.437. The company is just able to pay all its short-term debts.
  • The TTM is 1.590. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.437TTM1.590-0.152
TTM1.590YOY5.201-3.611
TTM1.5905Y4.123-2.534
5Y4.12310Y4.726-0.603
4.4.3.2. Quick Ratio

Measures if Evoke Pharma Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Evoke Pharma Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.37 means the company can pay off $1.37 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Evoke Pharma Inc:

  • The MRQ is 1.368. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 1.394. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ1.368TTM1.394-0.026
TTM1.394YOY4.676-3.282
TTM1.3945Y3.822-2.428
5Y3.82210Y4.446-0.624
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Evoke Pharma Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Evoke Pharma Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Evoke Pharma Inc to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.69 means that Evoke Pharma Inc assets are financed with 69.0% credit (debt) and the remaining percentage (100% - 69.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Evoke Pharma Inc:

  • The MRQ is 0.690. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.889. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.690TTM0.889-0.199
TTM0.889YOY0.874+0.015
TTM0.8895Y0.789+0.099
5Y0.78910Y0.650+0.139
4.5.4.2. Debt to Equity Ratio

Measures if Evoke Pharma Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Evoke Pharma Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 222.6% means that company has $2.23 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Evoke Pharma Inc:

  • The MRQ is 2.226. The company is just not able to pay all its debts with equity.
  • The TTM is 2.085. The company is just not able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.226TTM2.085+0.141
TTM2.085YOY5.326-3.240
TTM2.0855Y2.181-0.095
5Y2.18110Y1.786+0.395
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Evoke Pharma Inc generates.

  • Above 15 is considered overpriced but always compare Evoke Pharma Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -1.27 means the investor is paying $-1.27 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Evoke Pharma Inc:

  • The EOD is -1.149. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.269. Based on the earnings, the company is expensive. -2
  • The TTM is -0.483. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.149MRQ-1.269+0.120
MRQ-1.269TTM-0.483-0.786
TTM-0.483YOY-0.878+0.395
TTM-0.4835Y-0.599+0.116
5Y-0.59910Y-0.518-0.080
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Evoke Pharma Inc:

  • The EOD is -1.842. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.035. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.774. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.842MRQ-2.035+0.192
MRQ-2.035TTM-0.774-1.261
TTM-0.774YOY-1.029+0.255
TTM-0.7745Y-0.824+0.050
5Y-0.82410Y-0.621-0.203
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Evoke Pharma Inc is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Evoke Pharma Inc:

  • The EOD is 1.375. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.519. Based on the equity, the company is underpriced. +1
  • The TTM is 0.143. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.375MRQ1.519-0.144
MRQ1.519TTM0.143+1.376
TTM0.143YOY2.537-2.394
TTM0.1435Y-0.445+0.588
5Y-0.44510Y0.151-0.596
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Evoke Pharma Inc.

4.8.1. Institutions holding Evoke Pharma Inc

Institutions are holding 20.498% of the shares of Evoke Pharma Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-06-30Goldman Sachs Group Inc000-13471-100
2024-06-30Millennium Management LLC000-10869-100
2024-06-30Wells Fargo & Co000-66-100
2024-06-30Federation des caisses Desjardins du Quebec000-5-100
Total 000-24411-100

4.9.2. Funds holding Evoke Pharma Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Vanguard Institutional Extnd Mkt Idx Tr0.30360248700
2024-09-30Fidelity Extended Market Index0.298902449-905-26.9827
2024-09-30Fidelity Nasdaq Composite Index0.0455037300
2024-06-30SSgA U.S. Total Market Index Strategy0.002702677942.0213
2024-09-30Fidelity Series Total Market Index0.03024600
2024-09-30Northern Trust Extended Eq Market Idx0.0205016800
2024-09-30NT Ext Equity Mkt Idx Fd - L0.0205016800
2024-09-30NT Ext Equity Mkt Idx Fd - NL0.0123010100
2024-09-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.009908100
2024-09-30Spartan Total Market Index Pool E0.008507000
2024-10-31State St US Extended Mkt Indx NL Cl C0.006605400
2024-09-30BNYM Mellon SL Market Completion UC10.00560.000146-1-2.1277
2024-09-30Fidelity Total Market Index0.00504100
2024-09-30NT Ext Eq Mkt Indx Fd DC Lending Tier 50.003202600
2024-09-30Northern Trust Wilshire 50000.0023019-1-5
Total 0.77510.00016596-828-12.6%

5.3. Insider Transactions

Insiders are holding 4.586% of the shares of Evoke Pharma Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2020-12-14David A GonyerSELL239542.94
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets14,154
Total Liabilities9,766
Total Stockholder Equity4,387
 As reported
Total Liabilities 9,766
Total Stockholder Equity+ 4,387
Total Assets = 14,154

Assets

Total Assets14,154
Total Current Assets14,038
Long-term Assets115
Total Current Assets
Cash And Cash Equivalents 11,339
Net Receivables 2,023
Inventory 493
Other Current Assets 183
Total Current Assets  (as reported)14,038
Total Current Assets  (calculated)14,038
+/-0
Long-term Assets
Long-term Assets Other 115
Long-term Assets  (as reported)115
Long-term Assets  (calculated)115
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities9,766
Long-term Liabilities0
Total Stockholder Equity4,387
Total Current Liabilities
Other Current Liabilities 9,766
Total Current Liabilities  (as reported)9,766
Total Current Liabilities  (calculated)9,766
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock0
Retained Earnings -127,599
Other Stockholders Equity 131,986
Total Stockholder Equity (as reported)4,387
Total Stockholder Equity (calculated)4,387
+/-0
Other
Cash and Short Term Investments 11,339
Common Stock Shares Outstanding 1,400
Liabilities and Stockholders Equity 14,154
Net Debt -11,339
Net Working Capital 4,272



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-31
> Total Assets 
905
0
0
0
116
1,680
1,793
23,738
24,986
22,567
17,023
13,391
15,302
12,621
10,608
11,683
9,532
6,872
4,636
10,813
9,294
14,838
13,156
10,759
7,942
5,585
6,626
7,018
5,660
4,363
7,631
7,327
6,396
4,638
8,267
6,751
9,434
19,296
17,557
11,650
10,573
9,026
14,404
13,411
11,851
10,039
8,980
7,853
7,069
12,454
12,136
14,154
14,15412,13612,4547,0697,8538,98010,03911,85113,41114,4049,02610,57311,65017,55719,2969,4346,7518,2674,6386,3967,3277,6314,3635,6607,0186,6265,5857,94210,75913,15614,8389,29410,8134,6366,8729,53211,68310,60812,62115,30213,39117,02322,56724,98623,7381,7931,680116000905
   > Total Current Assets 
0
0
0
0
116
1,670
1,050
23,738
24,431
22,012
16,935
13,308
15,249
12,574
10,608
11,675
9,524
6,872
4,636
10,813
9,283
14,827
13,144
10,748
7,930
5,585
6,626
7,007
5,648
4,260
7,561
7,292
6,246
4,533
8,196
6,715
9,281
19,176
17,472
11,601
10,561
9,026
14,404
13,257
11,722
9,948
8,927
7,840
6,827
12,454
12,136
14,038
14,03812,13612,4546,8277,8408,9279,94811,72213,25714,4049,02610,56111,60117,47219,1769,2816,7158,1964,5336,2467,2927,5614,2605,6487,0076,6265,5857,93010,74813,14414,8279,28310,8134,6366,8729,52411,67510,60812,57415,24913,30816,93522,01224,43123,7381,0501,6701160000
       Cash And Cash Equivalents 
866
0
0
0
116
1,670
1,050
23,738
24,197
21,835
16,046
12,177
14,156
11,692
9,883
10,739
8,691
6,100
4,129
10,380
9,007
14,655
12,556
10,413
7,679
5,406
6,531
6,568
5,319
4,029
7,440
6,505
5,664
4,133
7,990
6,281
8,069
18,186
16,721
11,142
9,145
7,701
13,451
12,350
9,844
8,213
7,006
5,965
4,739
9,703
9,178
11,339
11,3399,1789,7034,7395,9657,0068,2139,84412,35013,4517,7019,14511,14216,72118,1868,0696,2817,9904,1335,6646,5057,4404,0295,3196,5686,5315,4067,67910,41312,55614,6559,00710,3804,1296,1008,69110,7399,88311,69214,15612,17716,04621,83524,19723,7381,0501,670116000866
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
336
23
128
198
222
295
419
366
675
625
687
1,024
1,234
673
1,452
2,003
2,023
2,0232,0031,4526731,2341,0246876256753664192952221981282333600000000000000000000000000000000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
86
236
236
234
225
186
279
268
220
289
365
514
505
482
589
545
493
4935455894825055143652892202682791862252342362368600000000000000000000000000000000000
   > Long-term Assets 
0
0
0
0
0
11
743
0
556
556
88
83
53
47
0
8
8
8
0
0
12
12
12
12
12
12
0
12
12
103
70
35
150
105
71
36
153
120
85
49
12
0
0
154
129
91
53
13
242
242
0
115
11502422421353911291540012498512015336711051503570103121201212121212120088804753838855655607431100000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
103
70
35
139
105
71
36
142
120
85
49
12
0
0
154
129
91
53
13
0
0
0
0
0000135391129154001249851201423671105139357010300000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
743
0
555
556
88
83
53
47
0
8
8
0
0
0
11
11
12
11
12
0
0
12
12
0
0
0
12
0
0
0
153,256
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000153,256000120001212001211121111000880475383885565550743000000
> Total Liabilities 
335
0
0
0
19,775
21,830
3,729
4,515
3,803
4,116
1,854
1,700
6,113
6,188
6,296
6,375
6,067
6,115
6,163
6,110
5,507
6,904
6,386
8,700
5,776
1,196
1,266
1,611
1,634
1,287
1,285
2,154
2,015
1,716
8,641
8,674
12,649
11,485
11,592
6,877
7,018
7,092
7,213
7,878
7,767
7,913
8,441
8,727
9,648
8,957
9,471
9,766
9,7669,4718,9579,6488,7278,4417,9137,7677,8787,2137,0927,0186,87711,59211,48512,6498,6748,6411,7162,0152,1541,2851,2871,6341,6111,2661,1965,7768,7006,3866,9045,5076,1106,1636,1156,0676,3756,2966,1886,1131,7001,8544,1163,8034,5153,72921,83019,775000335
   > Total Current Liabilities 
335
0
0
0
570
668
1,488
2,637
2,285
2,944
1,837
1,685
1,872
2,500
3,194
2,006
1,834
2,434
6,163
1,012
1,412
1,136
1,879
2,649
2,075
1,196
1,266
1,611
1,634
1,287
1,285
2,154
2,015
1,716
6,641
6,621
7,536
6,249
6,231
1,390
1,406
1,357
1,353
1,878
1,655
1,678
2,081
2,240
3,036
8,957
9,471
9,766
9,7669,4718,9573,0362,2402,0811,6781,6551,8781,3531,3571,4061,3906,2316,2497,5366,6216,6411,7162,0152,1541,2851,2871,6341,6111,2661,1962,0752,6491,8791,1361,4121,0126,1632,4341,8342,0063,1942,5001,8721,6851,8372,9442,2852,6371,488668570000335
       Short-term Debt 
0
0
0
0
0
0
701
1,070
1,443
1,443
0
0
150
713
1,252
0
146
709
4,400
0
146
0
0
0
0
0
0
0
0
103
70
35
139
105
175
140
246
120
85
49
12
0
0
140
129
91
53
13
5,000
5,000
5,000
0
05,0005,0005,0001353911291400012498512024614017510513935701030000000014604,40070914601,252713150001,4431,4431,070701000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
127
0
0
0
146
0
0
0
0
0
0
0
0
0
0
0
0
103
0
0
0
0
104
104
104
0
0
0
0
0
0
0
0
0
0
0
5,000
5,000
5,000
0
05,0005,0005,000000000000001041041040000103000000000000146000127000000000000
       Accounts payable 
89
0
0
0
97
0
601
1,567
842
1,501
1,837
1,685
1,709
1,778
1,937
2,003
1,688
1,726
1,763
1,012
1,412
1,136
1,879
2,649
2,075
1,196
1,266
1,611
1,634
1,184
1,215
2,119
1,877
1,611
605
766
1,274
691
519
531
874
944
824
1,021
934
1,186
1,415
1,397
1,712
1,640
1,900
0
01,9001,6401,7121,3971,4151,1869341,0218249448745315196911,2747666051,6111,8772,1191,2151,1841,6341,6111,2661,1962,0752,6491,8791,1361,4121,0121,7631,7261,6882,0031,9371,7781,7091,6851,8371,5018421,56760109700089
       Other Current Liabilities 
246
0
0
0
570
668
786
1,567
842
1,501
1,837
1,685
1,721
1,787
1,943
2,006
1,688
1,726
1,763
1,012
1,266
1,136
1,879
2,649
2,075
1,196
1,266
1,611
1,634
1,184
1,215
2,119
1,877
1,611
5,861
5,715
6,016
9
6
811
519
1,357
529
717
591
1,586
2,028
2,227
1,324
2,317
2,571
9,766
9,7662,5712,3171,3242,2272,0281,5865917175291,357519811696,0165,7155,8611,6111,8772,1191,2151,1841,6341,6111,2661,1962,0752,6491,8791,1361,2661,0121,7631,7261,6882,0061,9431,7871,7211,6851,8371,5018421,567786668570000246
   > Long-term Liabilities 
0
0
0
0
19,205
21,162
2,241
1,878
1,518
1,172
17
15
4,241
3,688
3,102
4,369
4,233
3,681
0
5,098
4,095
5,769
4,507
6,051
3,701
3,701
0
0
0
0
0
0
0
0
2,000
2,053
5,113
5,236
5,360
5,486
5,612
5,736
5,860
6,000
6,112
6,236
6,360
6,486
6,612
6,737
0
0
006,7376,6126,4866,3606,2366,1126,0005,8605,7365,6125,4865,3605,2365,1132,0532,000000000003,7013,7016,0514,5075,7694,0955,09803,6814,2334,3693,1023,6884,24115171,1721,5181,8782,24121,16219,2050000
       Long term Debt Total 
0
0
0
0
0
0
0
1,878
1,511
1,157
0
0
4,241
3,688
3,102
4,369
4,233
3,681
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,000
2,000
5,000
5,000
5,000
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000005,0005,0005,0002,0002,00000000000000000003,6814,2334,3693,1023,6884,241001,1571,5111,8780000000
       Other Liabilities 
0
0
0
0
0
0
0
0
7
16
17
15
0
0
0
0
0
0
0
5,098
4,095
5,768
4,507
6,050
3,701
0
0
0
0
0
0
0
0
0
0
53
113
236
360
486
612
736
860
986
1,112
1,236
1,360
0
0
0
0
0
000001,3601,2361,1129868607366124863602361135300000000003,7016,0504,5075,7684,0955,0980000000151716700000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
7
16
17
15
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000151716700000000
> Total Stockholder Equity
570
0
0
0
-19,659
-20,150
-1,936
19,223
21,183
18,451
15,169
11,691
9,189
6,433
4,312
5,308
3,465
757
-1,527
4,703
3,788
7,934
6,770
2,060
2,166
4,389
5,360
5,408
4,025
3,075
6,346
5,173
4,381
2,922
-374
-1,923
-3,215
7,811
5,966
4,773
3,555
1,934
7,191
5,533
4,085
2,126
538
-874
-2,580
3,497
2,665
4,387
4,3872,6653,497-2,580-8745382,1264,0855,5337,1911,9343,5554,7735,9667,811-3,215-1,923-3742,9224,3815,1736,3463,0754,0255,4085,3604,3892,1662,0606,7707,9343,7884,703-1,5277573,4655,3084,3126,4339,18911,69115,16918,45121,18319,223-1,936-20,150-19,659000570
   Common Stock
0
0
0
0
0
1
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
0
0
0
0
0
0
0
1
0
0
0010000000333333332222222222222111111111111110100000
   Retained Earnings Total Equity0000000000000-103,781-101,491-98,885-96,617-94,488-87,521-85,730-84,312-82,684-80,570-78,605-76,844-75,325-73,021-71,039-70,730-65,487-63,861-58,809-57,282-54,257-51,286-48,061-45,436-42,701-39,460-35,939-33,019-29,194-25,647-22,691-21,0750000000
   Accumulated Other Comprehensive Income 00000000000000000000000000000000000000000000-23,738,0530000000
   Capital Surplus 
0
0
0
0
0
0
0
40,297
43,874
44,097
44,363
44,709
45,127
45,893
47,012
50,743
51,525
52,042
52,729
61,984
62,596
71,793
72,256
72,788
73,203
77,409
80,683
82,250
82,628
83,644
89,028
89,483
90,108
90,440
94,112
94,691
95,668
109,299
109,744
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000109,744109,29995,66894,69194,11290,44090,10889,48389,02883,64482,62882,25080,68377,40973,20372,78872,25671,79362,59661,98452,72952,04251,52550,74347,01245,89345,12744,70944,36344,09743,87440,2970000000
   Treasury Stock0000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
196
198
18,653
40,297
43,874
44,097
44,363
44,709
45,127
45,893
47,012
50,743
51,525
52,042
52,729
61,984
62,596
71,793
72,256
72,788
73,203
77,409
80,683
82,250
82,628
83,644
89,028
89,483
90,108
90,440
94,112
94,691
95,668
109,299
109,744
110,521
110,975
111,527
119,021
119,376
119,731
120,016
120,296
120,578
120,860
128,516
128,951
131,986
131,986128,951128,516120,860120,578120,296120,016119,731119,376119,021111,527110,975110,521109,744109,29995,66894,69194,11290,44090,10889,48389,02883,64482,62882,25080,68377,40973,20372,78872,25671,79362,59661,98452,72952,04251,52550,74347,01245,89345,12744,70944,36344,09743,87440,29718,6531981960000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.